Development and validation of a circulating microRNA panel for the early detection of breast cancer
Menée à partir d'échantillons sériques prélevés sur 183 patientes atteintes d'un cancer du sein et 106 témoins puis validée sur 357 patientes supplémentaires et 396 témoins, cette étude évalue, en fonction de l'origine ethnique (européenne ou asiatique), la performance d'un panel de microARNs circulants pour détecter précocement un cancer du sein
Background : Mammography is widely used for breast cancer screening but suffers from a high false-positive rate. Here, we perform the largest comprehensive, multi-center study to date involving diverse ethnic groups, for the identification of circulating miRNAs for breast cancer screening.
Methods : This study had a discovery phase (n = 289) and two validation phases (n = 374 and n = 379). Quantitative PCR profiling of 324 miRNAs was performed on serum samples from breast cancer (all stages) and healthy subjects to identify miRNA biomarkers. Two-fold cross-validation was used for building and optimising breast cancer-associated miRNA panels. An optimal panel was validated in cohorts with Caucasian and Asian samples. Diagnostic ability was evaluated using area under the curve (AUC) analysis.
Results : The study identified and validated 30 miRNAs dysregulated in breast cancer. An optimised eight-miRNA panel showed consistent performance in all cohorts and was successfully validated with AUC, accuracy, sensitivity, and specificity of 0.915, 82.3%, 72.2% and 91.5%, respectively. The prediction model detected breast cancer in both Caucasian and Asian populations with AUCs ranging from 0.880 to 0.973, including pre-malignant lesions (stage 0; AUC of 0.831) and early-stage (stages I–II) cancers (AUC of 0.916).
Conclusions : Our panel can potentially be used for breast cancer screening, in conjunction with mammography.
British Journal of Cancer , article en libre accès, 2022